FDA Approves New Oral Treatment Combination for Advanced Breast Cancer With ESR1 Mutations
Federal regulators have approved a new once-daily pill combination for adults with advanced hormone receptor-positive breast cancer that has progressed despite previous hormone treatments.
❤️Conditions & CarePhoto: Medical Xpress
Key points
- FDA approved giredestrant combined with everolimus for specific advanced breast cancer cases.
- Targets patients with estrogen receptor-positive, HER2-negative tumors carrying ESR1 mutations.
- Clinical trial showed a median progression-free survival of 10 months compared to 5.5 months for standard care.
The U.S. Food and Drug Administration (FDA) has granted approval for giredestrant, marketed as Wilserdly, to be used alongside the cancer drug everolimus. This therapeutic pairing is authorized specifically for adults dealing with estrogen receptor-positive, HER2-negative breast cancer that has advanced into surrounding tissue or metastasized to other regions of the body. Over time, a significant portion of these tumors develop specific gene modifications known as ESR1 mutations, which allow them to evade standard hormone therapies. The approval applies exclusively to patients whose tumors carry this particular mutation and whose disease has worsened following prior endocrine treatments.
To identify eligible individuals, federal regulators simultaneously authorized a blood test called FoundationOne Liquid CDx, which detects circulating tumor DNA in the bloodstream. Giredestrant functions by binding to estrogen receptors on malignant cells to block the hormone and prompt receptor degradation, while everolimus inhibits a distinct pathway utilized by cancer cells for proliferation. The regulatory decision stems from a clinical trial involving 373 adults, including 207 participants with ESR1 mutations, where those receiving giredestrant achieved a median progression-free survival of 10 months compared to 5.5 months for patients receiving standard hormone therapy. Tumor shrinkage was observed in 27 percent of the giredestrant cohort, contrasted with 14 percent in the comparison group, though researchers noted it remains too early to determine if the regimen improves overall survival rates.
What to know: The recommended dosage is 30 milligrams daily, and reported side effects include fatigue, nausea, rash, diarrhea, and inflammation in mouth or lung tissues, alongside warnings regarding bradycardia and risks to developing fetuses. Patients should consult their healthcare provider to discuss personal treatment decisions and options.
Source Medical Xpress — medicalxpress.com/news/2026-11-pill-combo-breast-cancer-hormone.html ↗
Read next
🧠Mind & Mental HealthAddressing Body Image and the Reality of Gluteal Anatomy
A personal reflection on the social and psychological impact of body shape, specifically regarding the gluteal region, and the limitations of consumer solutions for perce…
🔬ResearchCBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities
A double-blind clinical trial published in JAMA Pediatrics indicates that CBD oil provides no significant behavioral improvement for children and teenagers with intellect…
🏃FitnessExpert Advice on Hydration Gear Sparks Debate Among Recreational Runners
Olympic medalist Josh Kerr recently suggested that runners may not require hydration packs for distances under 12 miles, igniting a broader conversation about gear necess…
🏃FitnessA Structured Approach to Beginning a Strength and Cardio Routine
A new four-week training program offers beginners a guided path to incorporating strength training and cardiovascular exercise into their daily lives.
🧠Mind & Mental HealthThe Role of Daily Mobility Training in Managing Sedentary Tension
A two-week personal trial suggests that incorporating short, daily mobility exercises may help alleviate stiffness associated with sedentary desk work. Experts note that …
🧠Mind & Mental HealthNew Theoretical Framework Explores Memory Formation and Dementia
Researchers have proposed a new model suggesting the brain's limbic system functions similarly to generative AI, potentially offering a new way to understand and classify…